ArticleJHEP reports : innovation in hepatology2026

A novel pharmacological inhibitor of MAP4K4 activity attenuates metabolic dysfunction-associated steatohepatitis.

Felix Ampadu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.